Search results
Results from the WOW.Com Content Network
Familial partial lipodystrophy, also known as Köbberling–Dunnigan syndrome, [2] is a rare genetic metabolic condition characterized by the loss of subcutaneous fat. [ 3 ] : 495 FPL also refers to a rare metabolic condition in which there is a loss of subcutaneous fat in the arms, legs and lower torso.
Familial Partial Lipodystrophy, Dunnigan Type Autosomal dominant is the manner of inheritance of this condition Dunnigan-type familial partial lipodystrophy , also known as FPLD Type II and abbreviated as ( FPLD2 ), is a rare monogenic form of insulin resistance characterized by loss of subcutaneous fat from the extremities , trunk , and ...
(Although, in some cases, rotation of the injection sites may not be enough to prevent lipodystrophy.) [citation needed] Some of the side-effects of lipodystrophy are the rejection of the injected medication, the slowing down of the absorption of the medication, or trauma which can cause bleeding that, in turn, causes rejection of the medication.
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. ... worsening pain in your upper right belly, usually about ...
The most common side effects include reduced platelet levels and reactions at the site of the injection such as pain, swelling, itching, or bruising. [ 5 ] Volanesorsen, is an 'antisense oligonucleotide,' a very short piece of synthetic RNA (a type of genetic material). [ 5 ]
Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia.It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired ...
Causes Genetic Lipoprotein lipase deficiency is a genetic disorder in which a person has a defective gene for lipoprotein lipase , which leads to very high triglycerides , which in turn causes stomach pain and deposits of fat under the skin, and which can lead to problems with the pancreas and liver , which in turn can lead to diabetes .
Standard guidelines for the management of renal disease should be followed. The course of membranoproliferative glomerulonephritis in acquired partial lipodystrophy has not been significantly altered by treatment with corticosteroids or cytotoxic medications. Recurrent bacterial infections, if severe, might be managed with prophylactic antibiotics.